**Name of Journal:** *Artificial Intelligence in Gastroenterology*

**Manuscript NO:** 63298

**Manuscript Type:** MINIREVIEWS

**Artificial intelligence in gastrointestinal diseases**

Tanabe S *et al*. AI in gastrointestinal diseases

Shihori Tanabe, Edward J Perkins, Ryuichi Ono, Hiroki Sasaki

**Shihori Tanabe,** Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, Kawasaki 210-9501, Japan

**Edward J Perkins,** Environmental Laboratory, US Army Engineer Research and Development Center, Vicksburg, MS 3180, United States

**Ryuichi Ono,** Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences, Kawasaki 210-9501, Japan

**Hiroki Sasaki,** Department of Clinical Genomics, Fundamental Innovative Oncology Core, National Cancer Center Research Institute, Tokyo 104-0045, Japan

**Author contributions:** Tanabe S designed the outline and coordinated the writing of the paper, performed the majority of the writing and editing, and prepared the figure and table; Perkins EJ performed the editing; Ono R and Sasaki H provided input into the writing the paper and performed the editing.

**Supported by** Japan Agency for Medical Research and Development (AMED), No. JP20ak0101093.

**Corresponding author: Shihori Tanabe, PhD, Senior Research Fellow,** Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki 210-9501, Japan. stanabe@nihs.go.jp

**Received:** January 27, 2021

**Revised:** April 9, 2021

**Accepted:** June 4, 2021

**Published online:**

**Abstract**

Artificial intelligence (AI) applications are growing in medicine. It is important to understand the current state of the AI applications prior to utilizing in disease research and treatment. In this review, AI application in the diagnosis and treatment of gastrointestinal diseases are studied and summarized. In most cases, AI studies had large amounts of data, including images, to learn to distinguish disease characteristics according to a human’s perspectives. The detailed pros and cons of utilizing AI approaches should be investigated in advance to ensure the safe application of AI in medicine. Evidence suggests that the collaborative usage of AI in both diagnosis and treatment of diseases will increase the precision and effectiveness of medicine. Recent progress in genome technology such as genome editing provides a specific example where AI has revealed the diagnostic and therapeutic possibilities of RNA detection and targeting.

**Key Words:** Artificial intelligence; Gastrointestinal disease; RNA; Therapeutic application; Inflammatory diseases

Tanabe S, Perkins EJ, Ono R, Sasaki H. Artificial intelligence in gastrointestinal diseases. *Artif Intell Gastroenterol* 2021; In press

**Core Tip:** The application of artificial intelligence (AI) in the diagnosis and treatment of disease is a promising approach in medicine. The application of AI approaches in gastrointestinal diseases is summarized and reviewed. AI holds great promise in medicine, but to safely and efficiently apply AI in medicine, the advantages and limitations should first be carefully considered.

**INTRODUCTION**

Recent studies have developed RNA editing using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system, which has made genome editing more accessible and has resulted in the development of many applications[1-3]. These new technologies have many advantages and disadvantages in their utilization, which are already being applied in medicinal situations. RNA editing has been recognized as a potential prognostic biomarker for cancer and prediction models have been developed with machine learning[4]. The utilization of artificial intelligence (AI) is rapidly expanding and is increasingly useful in understanding gastrointestinal (GI) diseases[5-7]. To better understand the use of AI-oriented diagnosis and treatment of diseases, it is important to determine how to raise the potential of AI and manage the human-AI interaction in diagnosis and therapeutics in diseases. AI technology has been combined with a massive amount of data to understand human activities[8]. Increasingly image data such as magnetic resonance imaging, X-ray, computed tomography scanning or endoscope in clinic will be utilized for the diagnosis of the diseases[9-12]. Currently, machine learning algorithms improve performance of gastrointestinal endoscopy by diagnosing the gastrointestinal diseases[13]. The application of AI has increased identification of patients with intestinal malignancies or premalignant lesions, and inflammatory or other nonmalignant diseases or lesions[14]. Computer-aided diagnosis (CAD) for colonoscopy would improve the quality of image-oriented diagnosis of colorectal cancer[15]. Classification of systems in AI-oriented disease management is summarized in Table 1.

**APPLICATION OF AI IN DIAGNOSIS OF GASTROINTESTINAL DISEASES**

There are several areas in which AI can advance the diagnosis of GI diseases. Diseases of interest for AI-oriented disease management are summarized in Figure 1.

***AI application in*** ***inflammatory diseases***

The diagnosis of GI diseases such as inflammatory bowel disease (IBD) including Crohn’s disease, a chronic inflammatory condition in the GI tract, and ulcerative colitis, which occurs in the colon, includes several fundamental laboratory tests including measurement of hemoglobin, hematocrit, blood urea nitrogen, creatinine, liver enzymes and C-reactive protein[16].

***AI application in tumor***

Recent progress in AI has resulted in predictive tools for the diagnosis of GI cancer classification, where network-based machine learning in colorectal and bladder organoid models predicts drug responders and non-responders using network analysis of pharmacogenomics data and the patient’s transcriptome[17]. Bioinformatic analyses of gene expression data have revealed common gene signatures in hypopharyngeal and esophageal squamous cell carcinoma, which may serve as diagnostic and therapeutic targets[18]. Balloon catheter tracking and visualization in GI tracking could be made more precise with AI guidance using image recognition[19]. Deep learning algorithms for image recognition can lead to more precise endoscopic diagnosis with improved sensitivity and specificity in upper GI tract diseases such as gastric cancer and Barrett’s esophagus[20]. Convolutional neural networks (CNNs) have generated liver imaging features and shown promise in predicting the metachronous liver metastasis in stage I-III colorectal cancer patients[21]. Deep learning of immunohistochemistry images of human colon tissues are used to improve the performance in detection of protein subcellular localization[22]. AI is poised to have a greater impact on GI endoscopy with publication of large datasets including multi-class images and video datasets that are useful for AI deep learning[23]. It seems that the performance of capsule endoscopy for diagnosing small bowel disease is improved using AI approaches[24]. An AI deep learning algorithm that can diagnose upper GI cancers with clinical endoscopic imaging data has been developed and validated[25]. CNNs in AI deep learning using numerous endoscopic image data have been developed that can detect and diagnose gastric cancer[26].

***AI application in other diseases and endoscopy***

Min *et al*[27] pointed out that one drawback of AI approaches is the need for large datasets to train the system; therefore, the quality of CNN-based AI endoscopy is limited by the need for a large number of high-quality endoscopic images. Machine learning and AI are important to diagnose functional GI disorders and aid healthcare professionals and researchers[28]. Ahmad *et al*[29] suggested that the level of AI and CAD in colonoscopy has reached that of human expert performance. A real-time AI system with deep learning technology has been developed to diagnose colorectal cancer[30]. An AI-oriented automated CAD system can identify histologic inflammation associated with ulcerative colitis[7]. Reismann *et al*[5] used AI to identify biomarker signatures to diagnose and classify the pediatric acute appendicitis.

**APPLICATION OF AI IN THERAPEUTICS OF GI DISEASES**

The application of AI in therapeutics of GI diseases has been expanding. The roles of AI in capsule endoscopy and other recent advanced diagnostic technologies have increased in therapeutics of GI diseases[31,32]. AI analysis was implemented to build neural network models enabling the classification of patients with biliary strictures and identify potential biomarkers in human bile[33]. Machine learning on medical examination records has stimulated the development of preventative measures for colorectal cancer[34]. Retrospective and prospective clinical studies have been conducted to diagnose and predict the prognosis of GI diseases including gastroesophageal reflux disease, atrophic corpus gastritis, acute pancreatitis, acute lower GI bleeding, esophageal cancer, nonvariceal upper GI bleeding, ulcerative colitis after cytoapheresis therapy, IBD, lymph node metastasis in T1 colorectal cancer and postoperative distant metastasis in esophageal squamous cell carcinoma[35]. Kather *et al*[36] found that deep learning can be used to predict microsatellite instability from histology in GI cancer. Azer[37] developed CNN models that can detect and classify colorectal polyps, which may increase colonoscopy application in appropriate colorectal cancer therapeutics. AI-guided tissue analysis has been developed that predicts stage III colon cancer outcomes, which may improve patient care with pathologists’ assistance[6]. Ebigbo *et al*[38] found that AI utilization can be used to classify the Barret esophagus cancer. An AI-based clinical decision-support system has been developed to diagnose celiac disease[39]. Bioinformatics analyses have identified important genes associated with the pathogenesis and prognosis of esophageal squamous cell carcinoma, which may contribute to the molecular-targeted therapy[40]. Long non-coding RNA signature has been identified in locally advanced rectal adenocarcinoma, which may predict the response to neoadjuvant chemoradiotherapy in the patients[41]. Machine learning has been utilized for identifying prognostic biomarkers in the whole blood of IBD patients to support the personalized therapy[42]. Ontology tools such as Experimental Factor Ontology or the Ontology of Biomedical Association may be useful for mining the disease-phenotype associations for IBD[43]. Since the responsiveness toward drug alters in cancer cell phenotypes such as epithelial-mesenchymal transition in diffuse-type gastric cancer, the AI application in the identification of cancer subtype would lead to establish therapeutic strategy[44,45]. The machine learning algorithms may be applied to the therapy of the GI diseases in terms of gut-brain axis[28,46].

**FUTURE PERSPECTIVES OF AI APPLICATION IN GI DISEASES**

Despite the rapid advances of the application of AI in GI diseases, there still remains some concern in terms of the precision of AI-based diagnosis and the criteria for the therapeutics. Further evidence is needed to solely rely on CAD in colonoscopy to determine an appropriate endpoint[15]. Some regulatory coordination may be needed to use the combination of an AI-assisted device and CAD software[15]. The differences in levels of AI performance would be considered and adjusted for application in clinical situations[14]. More high-quality datasets are needed to establish deep learning algorithms[14].

**CONCLUSION**

The area for AI application is rapidly expanding in the diagnosis and therapeutics of GI diseases. AI utilization in image recognition is currently being used to diagnose diseases and assist with personalized therapy. Future studies on disease-phenotype association are needed to maximize the capacity and performance of AI to aide in practical situations.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge the colleagues for their support.

**REFERENCES**

1 **Sternberg SH**, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature* 2014; **507**: 62-67 [PMID: 24476820 DOI: 10.1038/nature13011]

2 **Pickar-Oliver A**, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. *Nat Rev Mol Cell Biol* 2019; **20**: 490-507 [PMID: 31147612 DOI: 10.1038/s41580-019-0131-5]

3 **Jansen R**, Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. *Mol Microbiol* 2002; **43**: 1565-1575 [PMID: 11952905 DOI: 10.1046/j.1365-2958.2002.02839.x]

4 **Chen SC**, Lo CM, Wang SH, Su EC. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. *BMC Bioinformatics* 2019; **20**: 659 [PMID: 31870275 DOI: 10.1186/s12859-019-3236-0]

5 **Reismann J**, Romualdi A, Kiss N, Minderjahn MI, Kallarackal J, Schad M, Reismann M. Diagnosis and classification of pediatric acute appendicitis by artificial intelligence methods: An investigator-independent approach. *PLoS One* 2019; **14**: e0222030 [PMID: 31553729 DOI: 10.1371/journal.pone.0222030]

6 **Reichling C**, Taieb J, Derangere V, Klopfenstein Q, Le Malicot K, Gornet JM, Becheur H, Fein F, Cojocarasu O, Kaminsky MC, Lagasse JP, Luet D, Nguyen S, Etienne PL, Gasmi M, Vanoli A, Perrier H, Puig PL, Emile JF, Lepage C, Ghiringhelli F. Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. *Gut* 2020; **69**: 681-690 [PMID: 31780575 DOI: 10.1136/gutjnl-2019-319292]

7 **Maeda Y**, Kudo SE, Mori Y, Misawa M, Ogata N, Sasanuma S, Wakamura K, Oda M, Mori K, Ohtsuka K. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). *Gastrointest Endosc* 2019; **89**: 408-415 [PMID: 30268542 DOI: 10.1016/j.gie.2018.09.024]

8 **LeCun Y**, Bengio Y, Hinton G. Deep learning. *Nature* 2015; **521**: 436-444 [PMID: 26017442 DOI: 10.1038/nature14539]

9 **Ho TY**, Lin CW, Chang CC, Chen HT, Chen YJ, Lo YS, Hsiao PH, Chen PC, Lin CS, Tsou HK. Percutaneous endoscopic unilateral laminotomy and bilateral decompression under 3D real-time image-guided navigation for spinal stenosis in degenerative lumbar kyphoscoliosis patients: an innovative preliminary study. *BMC Musculoskelet Disord* 2020; **21**: 734 [PMID: 33172435 DOI: 10.1186/s12891-020-03745-w]

10 **Bhattacharya S**, Reddy Maddikunta PK, Pham QV, Gadekallu TR, Krishnan S SR, Chowdhary CL, Alazab M, Jalil Piran M. Deep learning and medical image processing for coronavirus (COVID-19) pandemic: A survey. *Sustain Cities Soc* 2021; **65**: 102589 [PMID: 33169099 DOI: 10.1016/j.scs.2020.102589]

11 **Karako K**, Song P, Chen Y, Tang W. Realizing 5G- and AI-based doctor-to-doctor remote diagnosis: opportunities, challenges, and prospects. *Biosci Trends* 2020; **14**: 314-317 [PMID: 33100291 DOI: 10.5582/bst.2020.03364]

12 **Shiyam Sundar LK**, Muzik O, Buvat I, Bidaut L, Beyer T. Potentials and caveats of AI in hybrid imaging. *Methods* 2021; **188**: 4-19 [PMID: 33068741 DOI: 10.1016/j.ymeth.2020.10.004]

13 **de Lange T**, Halvorsen P, Riegler M. Methodology to develop machine learning algorithms to improve performance in gastrointestinal endoscopy. *World J Gastroenterol* 2018; **24**: 5057-5062 [PMID: 30568383 DOI: 10.3748/wjg.v24.i45.5057]

14 **Le Berre C**, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. Application of Artificial Intelligence to Gastroenterology and Hepatology. *Gastroenterology* 2020; **158**: 76-94.e2 [PMID: 31593701 DOI: 10.1053/j.gastro.2019.08.058]

15 **Kudo SE**, Mori Y, Misawa M, Takeda K, Kudo T, Itoh H, Oda M, Mori K. Artificial intelligence and colonoscopy: Current status and future perspectives. *Dig Endosc* 2019; **31**: 363-371 [PMID: 30624835 DOI: 10.1111/den.13340]

16 **Wilkins T**, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. *Am Fam Physician* 2011; **84**: 1365-1375 [PMID: 22230271]

17 **Kong J**, Lee H, Kim D, Han SK, Ha D, Shin K, Kim S. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. *Nat Commun* 2020; **11**: 5485 [PMID: 33127883 DOI: 10.1038/s41467-020-19313-8]

18 **Zhou R**, Liu D, Zhu J, Zhang T. Common gene signatures and key pathways in hypopharyngeal and esophageal squamous cell carcinoma: Evidence from bioinformatic analysis. *Medicine (Baltimore)* 2020; **99**: e22434 [PMID: 33080677 DOI: 10.1097/MD.0000000000022434]

19 **Kim J**, Mai TT, Kim JY, Min JJ, Kim C, Lee C. Feasibility Study of Precise Balloon Catheter Tracking and Visualization with Fast Photoacoustic Microscopy. *Sensors (Basel)* 2020; **20** [PMID: 33003536 DOI: 10.3390/s20195585]

20 **Marlicz W**, Ren X, Robertson A, Skonieczna-Żydecka K, Łoniewski I, Dario P, Wang S, Plevris JN, Koulaouzidis A, Ciuti G. Frontiers of Robotic Gastroscopy: A Comprehensive Review of Robotic Gastroscopes and Technologies. *Cancers (Basel)* 2020; **12** [PMID: 32998213 DOI: 10.3390/cancers12102775]

21 **Lee S**, Choe EK, Kim SY, Kim HS, Park KJ, Kim D. Liver imaging features by convolutional neural network to predict the metachronous liver metastasis in stage I-III colorectal cancer patients based on preoperative abdominal CT scan. *BMC Bioinformatics* 2020; **21**: 382 [PMID: 32938394 DOI: 10.1186/s12859-020-03686-0]

22 **Xue ZZ**, Wu Y, Gao QZ, Zhao L, Xu YY. Automated classification of protein subcellular localization in immunohistochemistry images to reveal biomarkers in colon cancer. *BMC Bioinformatics* 2020; **21**: 398 [PMID: 32907537 DOI: 10.1186/s12859-020-03731-y]

23 **Borgli H**, Thambawita V, Smedsrud PH, Hicks S, Jha D, Eskeland SL, Randel KR, Pogorelov K, Lux M, Nguyen DTD, Johansen D, Griwodz C, Stensland HK, Garcia-Ceja E, Schmidt PT, Hammer HL, Riegler MA, Halvorsen P, de Lange T. HyperKvasir, a comprehensive multi-class image and video dataset for gastrointestinal endoscopy. *Sci Data* 2020; **7**: 283 [PMID: 32859981 DOI: 10.1038/s41597-020-00622-y]

24 **Adler SN**, Bjarnason I. What we have learned and what to expect from capsule endoscopy. *World J Gastrointest Endosc* 2012; **4**: 448-452 [PMID: 23189215 DOI: 10.4253/wjge.v4.i10.448]

25 **Luo H**, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. *Lancet Oncol* 2019; **20**: 1645-1654 [PMID: 31591062 DOI: 10.1016/S1470-2045(19)30637-0]

26 **Hirasawa T**, Aoyama K, Tanimoto T, Ishihara S, Shichijo S, Ozawa T, Ohnishi T, Fujishiro M, Matsuo K, Fujisaki J, Tada T. Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images. *Gastric Cancer* 2018; **21**: 653-660 [PMID: 29335825 DOI: 10.1007/s10120-018-0793-2]

27 **Min JK**, Kwak MS, Cha JM. Overview of Deep Learning in Gastrointestinal Endoscopy. *Gut Liver* 2019; **13**: 388-393 [PMID: 30630221 DOI: 10.5009/gnl18384]

28 **Mukhtar K**, Nawaz H, Abid S. Functional gastrointestinal disorders and gut-brain axis: What does the future hold? *World J Gastroenterol* 2019; **25**: 552-566 [PMID: 30774271 DOI: 10.3748/wjg.v25.i5.552]

29 **Ahmad OF**, Soares AS, Mazomenos E, Brandao P, Vega R, Seward E, Stoyanov D, Chand M, Lovat LB. Artificial intelligence and computer-aided diagnosis in colonoscopy: current evidence and future directions. *Lancet Gastroenterol Hepatol* 2019; **4**: 71-80 [PMID: 30527583 DOI: 10.1016/S2468-1253(18)30282-6]

30 **Yamada M**, Saito Y, Imaoka H, Saiko M, Yamada S, Kondo H, Takamaru H, Sakamoto T, Sese J, Kuchiba A, Shibata T, Hamamoto R. Development of a real-time endoscopic image diagnosis support system using deep learning technology in colonoscopy. *Sci Rep* 2019; **9**: 14465 [PMID: 31594962 DOI: 10.1038/s41598-019-50567-5]

31 **Yang YJ**. The Future of Capsule Endoscopy: The Role of Artificial Intelligence and Other Technical Advancements. *Clin Endosc* 2020; **53**: 387-394 [PMID: 32668529 DOI: 10.5946/ce.2020.133]

32 **Ciuti G**, Skonieczna-Żydecka K, Marlicz W, Iacovacci V, Liu H, Stoyanov D, Arezzo A, Chiurazzi M, Toth E, Thorlacius H, Dario P, Koulaouzidis A. Frontiers of Robotic Colonoscopy: A Comprehensive Review of Robotic Colonoscopes and Technologies. *J Clin Med* 2020; **9** [PMID: 32486374 DOI: 10.3390/jcm9061648]

33 **Urman JM**, Herranz JM, Uriarte I, Rullán M, Oyón D, González B, Fernandez-Urién I, Carrascosa J, Bolado F, Zabalza L, Arechederra M, Alvarez-Sola G, Colyn L, Latasa MU, Puchades-Carrasco L, Pineda-Lucena A, Iraburu MJ, Iruarrizaga-Lejarreta M, Alonso C, Sangro B, Purroy A, Gil I, Carmona L, Cubero FJ, Martínez-Chantar ML, Banales JM, Romero MR, Macias RIR, Monte MJ, Marín JJG, Vila JJ, Corrales FJ, Berasain C, Fernández-Barrena MG, Avila MA. Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. *Cancers (Basel)* 2020; **12** [PMID: 32575903 DOI: 10.3390/cancers12061644]

34 **Misawa D**, Fukuyoshi J, Sengoku S. Cancer Prevention Using Machine Learning, Nudge Theory and Social Impact Bond. *Int J Environ Res Public Health* 2020; **17** [PMID: 32012838 DOI: 10.3390/ijerph17030790]

35 **Yang YJ**, Bang CS. Application of artificial intelligence in gastroenterology. *World J Gastroenterol* 2019; **25**: 1666-1683 [PMID: 31011253 DOI: 10.3748/wjg.v25.i14.1666]

36 **Kather JN**, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, Marx A, Boor P, Tacke F, Neumann UP, Grabsch HI, Yoshikawa T, Brenner H, Chang-Claude J, Hoffmeister M, Trautwein C, Luedde T. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. *Nat Med* 2019; **25**: 1054-1056 [PMID: 31160815 DOI: 10.1038/s41591-019-0462-y]

37 **Azer SA**. Challenges Facing the Detection of Colonic Polyps: What Can Deep Learning Do? *Medicina (Kaunas)* 2019; **55** [PMID: 31409050 DOI: 10.3390/medicina55080473]

38 **Ebigbo A**, Mendel R, Probst A, Manzeneder J, Prinz F, de Souza LA Jr, Papa J, Palm C, Messmann H. Real-time use of artificial intelligence in the evaluation of cancer in Barrett's oesophagus. *Gut* 2020; **69**: 615-616 [PMID: 31541004 DOI: 10.1136/gutjnl-2019-319460]

39 **Tenório JM**, Hummel AD, Cohrs FM, Sdepanian VL, Pisa IT, de Fátima Marin H. Artificial intelligence techniques applied to the development of a decision-support system for diagnosing celiac disease. *Int J Med Inform* 2011; **80**: 793-802 [PMID: 21917512 DOI: 10.1016/j.ijmedinf.2011.08.001]

40 **Zhang H**, Zhong J, Tu Y, Liu B, Chen Z, Luo Y, Tang Y, Xiao F, Zhong J. Integrated Bioinformatics Analysis Identifies Hub Genes Associated with the Pathogenesis and Prognosis of Esophageal Squamous Cell Carcinoma. *Biomed Res Int* 2019; **2019**: 2615921 [PMID: 31950035 DOI: 10.1155/2019/2615921]

41 **Ferrando L**, Cirmena G, Garuti A, Scabini S, Grillo F, Mastracci L, Isnaldi E, Marrone C, Gonella R, Murialdo R, Fiocca R, Romairone E, Ballestrero A, Zoppoli G. Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma. *PLoS One* 2020; **15**: e0226595 [PMID: 32023246 DOI: 10.1371/journal.pone.0226595]

42 **Biasci D**, Lee JC, Noor NM, Pombal DR, Hou M, Lewis N, Ahmad T, Hart A, Parkes M, McKinney EF, Lyons PA, Smith KGC. A blood-based prognostic biomarker in IBD. *Gut* 2019; **68**: 1386-1395 [PMID: 31030191 DOI: 10.1136/gutjnl-2019-318343]

43 **Sarntivijai S**, Vasant D, Jupp S, Saunders G, Bento AP, Gonzalez D, Betts J, Hasan S, Koscielny G, Dunham I, Parkinson H, Malone J. Linking rare and common disease: mapping clinical disease-phenotypes to ontologies in therapeutic target validation. *J Biomed Semantics* 2016; **7**: 8 [PMID: 27011785 DOI: 10.1186/s13326-016-0051-7]

44 **Tanabe S**, Quader S, Cabral H, Ono R. Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies. *Front Pharmacol* 2020; **11**: 904 [PMID: 32625096 DOI: 10.3389/fphar.2020.00904]

45 **Tanabe S**, Quader S, Ono R, Cabral H, Aoyagi K, Hirose A, Yokozaki H, Sasaki H. Molecular Network Profiling in Intestinal- and Diffuse-Type Gastric Cancer. *Cancers (Basel)* 2020; **12** [PMID: 33353109 DOI: 10.3390/cancers12123833]

46 **Kano M**, Dupont P, Aziz Q, Fukudo S. Understanding Neurogastroenterology From Neuroimaging Perspective: A Comprehensive Review of Functional and Structural Brain Imaging in Functional Gastrointestinal Disorders. *J Neurogastroenterol Motil* 2018; **24**: 512-527 [PMID: 30041284 DOI: 10.5056/jnm18072]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 27, 2021

**First decision:** March 29, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): E, E

**P-Reviewer:** Eccher A, Hanada E, Liu Y **S-Editor:** Gao CC **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**



**Figure 1 Disease of interest in references surveyed in artificial intelligence-oriented disease management.** AI: Artificial intelligence; COVID-19: Coronavirus disease 2019.

**Table 1 Classification of systems in artificial intelligence-oriented disease management**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Disease of interest  | Purpose of AI | User | Limitation of use | Ref. |
| Acute appendicitis | Diagnosis | Specialist | The study is designed in retrospective nature | Reismann *et al*[5] |
| Colon cancer | Diagnosis | Specialist | The design of the analysis is post hoc and the number of patients is limited | Reichling *et al*[6] |
| Ulcerative colitis | Diagnosis | Specialist | Long-term clinical prognosis is not clear | Maeda *et al*[7] |
| Spinal stenosis in degenerative lumbar kyphoscoliosis | Surgery navigation | Specialist | The number of patients is limited. Long-term follow-up data is needed | Ho *et al*[9] |
| Coronavirus infectious disease (COVID-19) | Screening, diagnosis | Specialist | Privacy of the patient data should be considered | Bhattacharya *et al*[10] |
| Diseases in general | Diagnosis | Specialist | The burden on specialists may increase | Karako *et al*[11] |
| Diseases in general | Screening | Specialist | Careful and thorough investigation is necessary | Shiyam Sundar *et al*[12] |
| Gastrointestinal disease | Diagnosis | Specialist | There is a difference in the definition of anomaly detection between the area of computer science and medical domain | de Lange *et al*[13] |
| Gastrointestinal disease, hepatic diseases | Diagnosis | Specialist | High-quality datasets are needed | Le Berre *et al*[14] |
| Colorectal cancer | Diagnosis | Specialist | The quality of previous study designs is limited, and practical usefulness of computer-associated diagnosis systems is unknown | Kudo *et al*[15] |
| Colorectal cancer, bladder cancer | Prediction of anti-cancer drug efficacy | Specialist | Further molecular layer profiling in organoids may be needed | Kong *et al*[17] |
| Hypopharyngeal squamous cell carcinoma, esophageal squamous cell carcinoma | Identification of diagnostic and therapeutic targets | Specialist | Further studies are needed to validate the findings of the study | Zhou *et al*[18] |
| Arterial stenosis, coronary arterial diseases, stricture of the gastrointestinal tract | Guiding of balloon catheter | Specialist | The systemic performance needs to be improved | Kim *et al*[19] |
| Gastrointestinal disease | Diagnosis | Specialist | Further studies are needed to improve the performance | Marlicz *et al*[20] |
| Colorectal cancer | Prediction of liver metastasis | Specialist | The investigation of another dataset is needed | Lee *et al*[21] |
| Colon cancer | Diagnosis | Specialist | The change of protein expression level needs to be investigated | Xue *et al*[22] |
| Gastrointestinal disease | Diagnosis | Specialist | Investigation and development of newly improved methods are encouraged | Borgli *et al*[23] |
| Gastrointestinal disease | Diagnosis | Specialist | Further development is needed | Adler and Bjarnason[24] |
| Upper gastrointestinal cancer | Diagnosis | Specialist | Only high-quality endoscopic images for the training and validation analyses were used | Luo *et al*[25] |
| Gastric cancer | Diagnosis | Specialist | The associations of the quality or the number of training images and the CNN accuracy needs to be examined | Hirasawa *et al*[26] |
| Gastrointestinal disease | Diagnosis | Specialist | The possibilities to improve the medical performance, to reduce the medical cost, and to improve the satisfaction of the patient and medical staff are unknown | Min *et al*[27] |
| Functional gastrointestinal disorder | Diagnosis | Specialist | Evaluation of the feasibility of AI on studies on the gut-brain-microbiome axis is needed | Mukhtar *et al*[28] |
| Colorectal cancer | Diagnosis | Specialist | The uncertainty about the true efficacy of CAD in “real-world” practice remains | Ahmad *et al*[29] |
| Colorectal cancer | Diagnosis | Specialist | Further accumulation of lesion images for training is needed | Yamada *et al*[30] |
| Small-bowel disease | Diagnosis | Specialist | Further multicenter, prospective studies and external validation are needed | Yang[31] |
| Colorectal cancer | Diagnosis | Specialist | Complaints of system malfunctions and reports of patient injuries could lead to lawsuits against stakeholders | Ciuti *et al*[32] |
| Cholangiocarcinoma, pancreatic adenocarcinoma | Diagnosis | Specialist | Case-control and single-center design, and the lack of an independent validation cohort should be considered | Urman *et al*[33] |
| Colorectal cancer | Screening | Specialist | The applicability to other types of cancer needs optimization | Misawa *et al*[34] |
| Gastrointestinal disease | Diagnosis | Specialist | Most studies were designed in retrospective manner. Ethical issues on misdiagnosis or misclassification need to be handled | Yang and Bang[35] |
| Gastrointestinal cancer | Prediction of microsatellite instability for immunotherapy | Specialist | Larger training cohorts are needed | Kather *et al*[36] |
| Colorectal cancer | Diagnosis | Specialist | The CNN architecture needs to be improved for colonoscopy | Azer[37] |
| Barrett esophagus cancer | Diagnosis | Specialist | The number of patients is limited. Further optimization is needed | Ebigbo *et al*[38] |
| Celiac disease | Diagnosis | Specialist | The preliminary results need to be followed-up with a real clinical setting | Tenório *et al*[39] |
| Esophageal squamous cell carcinoma | Prediction of prognosis | Specialist | Further experimental studies to verify the results are needed | Zhang *et al*[40] |
| Advanced rectal adenocarcinoma | Prediction of response to neoadjuvant chemoradiotherapy | Specialist | The size of the cohort is limited. The confirmation of the findings with another data set is needed | Ferrando *et al*[41] |
| Inflammatory bowel disease | Prediction of prognosis | Specialist | Interventional study to confirm the efficacy of the stratifying therapy is needed | Biasci *et al*[42] |
| Inflammatory bowel disease | Mapping | Specialist | The application of advanced natural language processing algorithms to the text-mining step may improve the current process | Sarntivijai *et al*[43] |

AI: Artificial intelligence; CAD: Computer-aided diagnosis; CNN: Convolutional neural network.